Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

A CEO's Perspective of Investing in Biotechs with Al Altomari, CEO of Agile Therapeutics

A CEO's Perspective of Investing in Biotechs with Al Altomari, CEO of Agile Therapeutics

FromThe 7investing Podcast


A CEO's Perspective of Investing in Biotechs with Al Altomari, CEO of Agile Therapeutics

FromThe 7investing Podcast

ratings:
Length:
28 minutes
Released:
Nov 9, 2021
Format:
Podcast episode

Description

Investing in general can be complicated. Investing in an industry one doesn’t understand well, and doing so successfully can be close to impossible. The biotech industry is like that for many people. The science in general can be confusing, and with scientific discovery, there are many unknowns. This makes investing in the industry even more challenging. 7investing Lead Advisor Dana Abramovitz talks about investing in biotechs with Agile Therapeutics CEO Al Altomari.
Agile Therapeutics is a commercialization stage biotech focused on women’s health. Listening to women and targeting unmet needs, the company is developing contraceptives using its patch technology. It is focusing on commercialization of products rather than drug research and development, utilizing its core competencies to work with OB/GYNs and their patients to get women the therapeutics they need and want. Altomari discusses the importance of listening to users to meet the needs of the market and surrounding himself with a diverse team and board.
Describing the biotech industry, Altomari sees many partnerships and lots of collaboration. He suggests that everyone can learn from each other and share their knowledge with others. This follows the mindset of the scientific community, which publishes and reports at conferences, pushing scientific knowledge forward.
Altomari points out that investing in biotech companies is comparable to long term investing. Many biotech companies are still in the early stages of business development and it takes a long time to get to market and then for drugs to be prescribed by physicians. He also points out that there are not many milestones or catalysts to report on that might move the market in any one direction, especially for a small biotech company like Agile Therapeutics. As the CEO of a company in a volatile market, Altomari has to be comfortable with what his company is doing and how they are doing it and can’t let the swings of the market influence him.

Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year.
Start your journey toward's financial independence: https://www.7investing.com/subscribe
Stop by our website to level-up your investing education:  https://www.7investing.com
Follow us:
► https://www.facebook.com/7investing
► https://twitter.com/7investing
► https://instagram.com/7investing

---

Send in a voice message: https://podcasters.spotify.com/pod/show/7investing/message
Released:
Nov 9, 2021
Format:
Podcast episode

Titles in the series (100)

Welcome to 7investing.com. Our mission is to empower you to invest in your future. This podcast brings our market-based experts together to discuss our investing process and important news. Once a month, we will also feature interviews with some of the best minds in business and investing. Check out 7investing.com to find more of our free content and premium monthly stock recommendations.